The National Cancer Institute is offering funding to accelerate the translation of NCI-supported biomarker assays to clinical use for cancer detection, diagnosis, prognosis, and treatment monitoring. This grant aims to support the adaptation and validation of molecular, cellular, and imaging markers for improved cancer control and prevention. Projects should focus on acquiring annotated specimens for clinical validation, encouraging collaboration among scientists, clinicians, statisticians, and laboratory staff. This opportunity does not fund early-stage technology development or clinical trials, but rather the integration of validated assays into clinical trials. Closing date: Oct 28, 2022.
Opportunity ID: 322975
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-074 |
| Funding Opportunity Title: | Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 10, 2019 |
| Last Updated Date: | Dec 10, 2019 |
| Original Closing Date for Applications: | Oct 28, 2022 |
| Current Closing Date for Applications: | Oct 28, 2022 |
| Archive Date: | Dec 03, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $150,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments County governments City or township governments Independent school districts Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as “assays”) to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as “markers” r “biomarkers”) for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-074.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 322975 Full Announcement-PAR-20-074 -> PAR-20-074-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00259079 | Jan 28, 2020 | Jan 24, 2022 | View | |
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00257070 | Jan 28, 2020 | May 24, 2020 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00269751 | Oct 28, 2021 | Oct 28, 2022 | View |
Package 1
Mandatory forms
322975 RR_SF424_2_0-2.0.pdf
322975 PHS398_CoverPageSupplement_5_0-5.0.pdf
322975 RR_OtherProjectInfo_1_4-1.4.pdf
322975 PerformanceSite_2_0-2.0.pdf
322975 RR_KeyPersonExpanded_2_0-2.0.pdf
322975 PHS398_ResearchPlan_4_0-4.0.pdf
322975 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
322975 RR_Budget_1_4-1.4.pdf
322975 RR_SubawardBudget30_1_4-1.4.pdf
322975 PHS398_ModularBudget_1_2-1.2.pdf
322975 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
322975 RR_SF424_2_0-2.0.pdf
322975 PHS398_CoverPageSupplement_4_0-4.0.pdf
322975 RR_OtherProjectInfo_1_4-1.4.pdf
322975 PerformanceSite_2_0-2.0.pdf
322975 RR_KeyPersonExpanded_2_0-2.0.pdf
322975 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
322975 RR_Budget_1_4-1.4.pdf
322975 RR_SubawardBudget30_1_4-1.4.pdf
322975 PHS398_ModularBudget_1_2-1.2.pdf
322975 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 3
Mandatory forms
322975 RR_SF424_5_0-5.0.pdf
322975 PHS398_CoverPageSupplement_5_0-5.0.pdf
322975 RR_OtherProjectInfo_1_4-1.4.pdf
322975 PerformanceSite_4_0-4.0.pdf
322975 RR_KeyPersonExpanded_4_0-4.0.pdf
322975 PHS398_ResearchPlan_4_0-4.0.pdf
322975 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
322975 RR_Budget_3_0-3.0.pdf
322975 RR_SubawardBudget30_3_0-3.0.pdf
322975 PHS398_ModularBudget_1_2-1.2.pdf
322975 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
